BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18537861)

  • 1. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression.
    Lee C; Ramirez JA; Guitart J; Diaz LK
    J Cutan Pathol; 2008 Nov; 35(11):989-94. PubMed ID: 18537861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors.
    Nijsten T; Geluyckens E; Colpaert C; Lambert J
    J Cutan Pathol; 2005 May; 32(5):340-7. PubMed ID: 15811118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
    Pancione M; Forte N; Sabatino L; Tomaselli E; Parente D; Febbraro A; Colantuoni V
    Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.
    Kuzbicki L; Lange D; Chwirot BW
    Melanoma Res; 2009 Oct; 19(5):294-300. PubMed ID: 19543125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
    Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
    Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
    Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
    Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
    Kuźbicki L; Sarnecka A; Chwirot BW
    Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of muscarinic receptor subtype M3 in melanomas and their metastases.
    Oppitz M; Busch C; Garbe C; Drews U
    J Cutan Pathol; 2008 Sep; 35(9):809-15. PubMed ID: 18422974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nestin expression in cutaneous melanomas and melanocytic nevi.
    Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
    J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of COX-2 protein expression in melanocytic nevi in children].
    Kubus M; Andrzejewska E; Nejc D; Kobos J; Taran K
    Pol Merkur Lekarski; 2013 Aug; 35(206):82-4. PubMed ID: 24052986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the ets-1 proto-oncogene in melanocytic lesions.
    Keehn CA; Smoller BR; Morgan MB
    Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.